Eva Hellström-Lindberg group
Our research aims at improving overall and symptom-free survival in MDS and is pursued along the following lines:
- Clinical trials within the Nordic MDS Group: www.nmds.org
- Large sequencing projects encompassing DNA and RNA sequencing aiming for personalized prognostication.
- Hemopoietic stem cell (HSC) studies in specific MDS subtypes aiming to understand clonal hierarchies, mechanisms for HSC-niche interactions, and response to therapy. In particular we study patients who undergo stem cell transplantation in the Nordic region.
- Studies of the MDS subtype refractory anemia with ring sideroblasts, MDS-RS, exploring the biological consequences of mutations in the splice factor gene SF3B1 for HSC clonal advantage and anemia, respectively.
- Knut and Alice Wallenberg Foundation
- The Swedish Cancer Society
- The Scientific Research Council
- Stockholm County Council Research funds
- Cancer Society in Stockholm
- Nordic Cancer Union
Teresa Mortera Blanco, PhD, Senior Lab manager
Monika Jansson, Med Lic, Lab manager
Marios Dimitriou, Associate professor
Martin Jädersten, MD, PhD, Senior post doc
Magnus Tobiasson, MD, PhD, Senior post doc
Gabriele Todisco, MD, Post doc
Isabel Hofman, PhD, post doc
Edda Elvarsdottir, PhD student
Maria Creignou, MD, PhD PhD student
Sara von Bahr Grebäck, PhD, Administrator
Annette Öster Fernström, PhD, Administrator
Gunilla Walldin, Research and biobank nurse
Ann-Charlotte Björklund, technician
Indira Barbosa, technician
Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M. Elvarsdottir E, Conte S. Tobiasson M, Jansson M, Douagi I, Moari M, Saft L, Papaemmanuil E, Jacobsen, SEW. Hellström-Lindberg E. SF3B1 mutations in myelodysplastic syndromes with ring sideroblasts arise in multipotent hematopoietic stem cells. Blood. 2017 Aug 17;130(7):881-890.